You searched for side effects - Page 53 of 311 - Medivizor
Navigation Menu

Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?

Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?

Posted by on Jun 13, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs. Some background ARDs include chronic, inflammatory conditions such as...

Read More

Does high dose of thoracic radiotherapy improve the survival of patients with limited-stage small cell lung cancer?

Does high dose of thoracic radiotherapy improve the survival of patients with limited-stage small cell lung cancer?

Posted by on Jun 13, 2021 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the safety, tolerability, and effectiveness of high-dose thoracic radiotherapy for limited-stage (LS) small-cell lung cancer patients (SCLC). The study concluded the high dose of thoracic radiotherapy improved the survival of these patients without increasing toxicity.  Some background Lung cancer...

Read More

Is dabrafenib with trametinib treatment effective before surgery for patients with unresectable advanced-stage melanoma?

Is dabrafenib with trametinib treatment effective before surgery for patients with unresectable advanced-stage melanoma?

Posted by on Jun 13, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness of dabrafenib (Tafinlar) plus trametinib (Mekinist) treatment before surgery for patients with unresectable advanced-stage melanoma. The data showed that this treatment was effective before surgery and allowed for the removal of tumors. Some background Melanoma is an aggressive type of skin...

Read More

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Long-term treatment-free remission for patients with chronic phase chronic myeloid leukemia after second line nilotinib treatment 

Posted by on Jun 13, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate long-term treatment-free remission (TFR) for patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were treated with nilotinib (Tasigna) as a second-line treatment.   This study concluded that TFR is safe and durable in these patients.   Some background The...

Read More

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Posted by on Jun 12, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...

Read More

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Posted by on Jun 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects. Some background...

Read More

Comparing enucleation and resection for BPH in medium-sized prostates

Comparing enucleation and resection for BPH in medium-sized prostates

Posted by on Jun 6, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study compared the effectiveness and safety of holmium laser enucleation of the prostate (HoLEP), bipolar transurethral enucleation of the prostate (bTUEP), and transurethral resection of the prostate (TURP) for patients with benign prostatic hyperplasia (BPH) in medium-sized prostates. The authors concluded that all...

Read More

Helicobacter pylori treatment improves symptoms in patients with advanced Parkinson’s disease

Helicobacter pylori treatment improves symptoms in patients with advanced Parkinson’s disease

Posted by on Jun 6, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study investigated how Helicobacter pylori (HP) infection and its treatment affect the treatment of Parkinson’s disease (PD). Researchers suggested that HP treatment improves the symptoms of patients with PD. Some background PD commonly affects older people. It affects the brain cells causing symptoms such...

Read More

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to investigate FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) before pre-surgery chemoradiotherapy (CRT) for patients with rectal cancer (RC). The study found that FOLFIRINOX given before CRT and surgery improved the outcomes of these patients. Some background RC can be treated with...

Read More

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Posted by on Jun 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...

Read More